BioCentury
ARTICLE | Clinical News

EC approves rare disease drug from Chiesi

April 6, 2018 2:49 PM UTC

Chiesi Farmaceutici S.p.A. (Parma, Italy) said the European Commission approved an MAA for Lamzede velmanase alfa to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis, a rare lysosomal storage disease...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Chiesi Farmaceutici S.p.A.